Literature DB >> 12769214

Hepatic radiofrequency ablation of metastatic ovarian granulosa cell tumors.

Ira A Jacobs1, C K Chang, George Salti.   

Abstract

Intrahepatic recurrences of a granulosa cell tumor of the ovary after primary resection has traditionally been considered a relative contraindication to surgical management. Improvements in ablative technologies such as radiofrequency ablation (RFA) offer the surgeon additional alternatives in the management of selected intrahepatic tumors. We present a case report of an intrahepatic recurrence of a metastatic ovarian granulosa cell tumor 6 months after primary resection. The patient received RFA of the intrahepatic lesions and the patient remains free of detectable disease 14 months later. A review of the literature is presented. This is the first known report of the use of RFA for intrahepatic recurrence of a metastatic ovarian granulosa cell tumor. In selected cases of metastatic ovarian granulosa cell tumors to the liver RFA may increase the percentage of patients considered surgically treatable.

Entities:  

Mesh:

Year:  2003        PMID: 12769214

Source DB:  PubMed          Journal:  Am Surg        ISSN: 0003-1348            Impact factor:   0.688


  3 in total

Review 1.  Local recurrence after hepatic radiofrequency coagulation: multivariate meta-analysis and review of contributing factors.

Authors:  Stefaan Mulier; Yicheng Ni; Jacques Jamart; Theo Ruers; Guy Marchal; Luc Michel
Journal:  Ann Surg       Date:  2005-08       Impact factor: 12.969

Review 2.  Hepatic resection during cytoreductive surgery for primary or recurrent epithelial ovarian cancer.

Authors:  Maria Luisa Gasparri; Giovanni Grandi; Daniele Bolla; Beat Gloor; Sara Imboden; Pierluigi Benedetti Panici; Michael D Mueller; Andrea Papadia
Journal:  J Cancer Res Clin Oncol       Date:  2015-12-11       Impact factor: 4.553

3.  Metastasis of the liver with a granulosa cell tumor of the ovary: A case report.

Authors:  Shuiping Yu; Xueling Zhou; Binzong Hou; Bo Tang; Jie Hu; Songqing He
Journal:  Oncol Lett       Date:  2014-12-09       Impact factor: 2.967

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.